Company intelligence / Profile preview

Calithera Biosciences

South San Francisco, California, United States

Ownership: Public · CALA
Employees: ~8
Development stage: Other

Overview

Calithera reached Phase 2 for several programs targeting cancers with genetic vulnerabilities, including glutaminase, SYK, and mTOR inhibitors, but clinical setbacks (notably telaglenastat in renal cell carcinoma) in 2022 led to business wind-down and a plan of liquidation in 2023.[1][3][4][6][9]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

4 assets

mivavotinib

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbTakedaPfizer

Financials

Market cap: $1.9K
Total revenue: $0
Enterprise value: $-23.8M

Beyond the preview

Go deeper on Calithera Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calithera Biosciences.

Explore the full profile